<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02368964</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-14-1817-YH-CTIL</org_study_id>
    <nct_id>NCT02368964</nct_id>
  </id_info>
  <brief_title>IVF Treatment in Women With Immature Oocytes in Previous Cycle</brief_title>
  <official_title>Treatment for Final Follicular Maturation Induction in Patients With Previous High Ratio of Immature Oocytes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In standard IVF stimulation cycle,human chorionic gonadotropin (hCG) is usually used at the
      end of controlled ovarian hyperstimulation (COH) as a surrogate to only the luteinizing
      hormone (LH) surge. Yet, the last dose of follicle stimulating hormone (FSH) is usually given
      between 12-24 hours before the hCG triggering dose.One protocol used at the investigators
      unit, after a cycle with low proportion of mature oocytes per number oocytes retrieved, is
      triggering with high dose hCG (500 mcg)-38 hours prior to oocyte aspiration.

      Lately, new researches showed that dual triggering of final oocyte maturation with a
      combination of GnRH- agonist and hCG, could improve the live-birth rate of normal responders
      undergoing the GnRH-antagonist COH protocol

      Another treatment option is high dose hCG. Only few case reports have described the use of
      high dose hCG after aspiration of non mature oocytes at a previous cycle. At the
      investigators IVF unit, patients with previous history of high percentage of immature oocytes
      retrieved, are triggered at the following cycle, either with double trigger or with high dose
      of hCG decided by the physician consulting the patient. It is still not known with which way
      of triggering more mature oocytes is retrieved.

      The aim of this study is to perform a prospective randomized controlled study in patients
      with low proportion of mature-MII oocytes oocytes (&lt;75%) per number oocytes retrieved,
      despite normal response to controlled ovarian hyperstimulation ( COH ) comparing cycles
      triggered with high dose hCG to those triggered with hCG+GnRH agonist.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be prospectively randomized into two groups. The randomization will be
      organized through the computer. The hCG group- will be triggered for final follicular
      maturation with high dose hCG (500 mcg)-38 hours prior to oocyte aspiration, and the Double
      trigger Group- will receive gonadotropin-releasing hormone (GnRH) agonist (Decapeptyl 0.2mg)
      40 hours prior to oocyte aspiration and hCG (250mcg) 34 hours prior to the oocyte aspiration.
      All patients will be supplemented with the same progesterone preparation( Crinone gel 8% once
      a day) for luteal support. Women that suffer from vaginal spotting or vaginal bleeding during
      the luteal phase will receive supplementation of Geston 50MG intramuscular once every 2 days.

      At the day of oocyte aspiration, blood will be drawn for serum LH, FSH, estrogen (E2) and
      progesterone. Moreover, clear follicular fluid will be collected and tested for LH, FSH, E2
      and progesterone levels.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number MII oocytes per number of oocytes retrieved</measure>
    <time_frame>day of retrieving the oocytes</time_frame>
    <description>Rate of mature oocytes from total oocytes retrieved</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total oocytes</measure>
    <time_frame>day of retrieving the oocytes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>Two weeks from induction of ovulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of top quality embryos</measure>
    <time_frame>day of retrieving the oocytes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>High dose hCG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The hCG group- will be triggered for final follicular maturation with high dose hCG (500 mcg)-38 hours prior to oocyte aspiration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double trigger</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double trigger Group- will receive GnRH agonist (Decapeptyl 0.2mg) 40 hours prior to oocyte aspiration and hCG (250mcg) 34 hours prior to the oocyte aspiration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH agonist 0.2 mg + hCG 250 mcg</intervention_name>
    <description>Treatment for triggering</description>
    <arm_group_label>Double trigger</arm_group_label>
    <other_name>GnRH agonist - Decapeptyl , hCG - Ovitrelle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose hCG 500 mcg</intervention_name>
    <description>Treatment for triggering</description>
    <arm_group_label>High dose hCG</arm_group_label>
    <other_name>Ovitrelle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with low proportion of mature-MII oocytes oocytes (75%) per number oocytes
             retrieved at the prior IVF cycle

          -  Age between 18-42

        Exclusion Criteria:

          -  Women with high ovarian response:anti-mullerian hormone ( AMH) &gt;5, antral follicle
             count ( AFC) &gt;15

          -  more than 20 oocytes retrieved at the prior cycle.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aya Mohr Sasson, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center - IVF Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aya Mohr Sasson, M.D</last_name>
    <email>mohraya@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eve Keret</last_name>
    <email>Eve.Keret@sheba.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://www.fertstert.org/article/S0015-0282(14)00388-4/references</url>
    <description>Griffin D, Feinn R, Engmann L, Nulsen J, Budinetz T, Benadiva C. Dual trigger with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin to improve oocyte maturity rates. Fertility and sterility 2014;102:405-9.</description>
  </link>
  <reference>
    <citation>Lamb JD, Shen S, McCulloch C, Jalalian L, Cedars MI, Rosen MP. Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization cycles: a randomized, double-blind, placebo-controlled trial. Fertil Steril. 2011 Apr;95(5):1655-60. doi: 10.1016/j.fertnstert.2011.01.019.</citation>
    <PMID>21315341</PMID>
  </reference>
  <reference>
    <citation>Lin MH, Wu FS, Lee RK, Li SH, Lin SY, Hwu YM. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles. Fertil Steril. 2013 Nov;100(5):1296-302. doi: 10.1016/j.fertnstert.2013.07.1976. Epub 2013 Aug 28.</citation>
    <PMID>23993928</PMID>
  </reference>
  <reference>
    <citation>Zilberberg E, Haas J, Dar S, Kedem A, Machtinger R, Orvieto R. Co-administration of GnRH-agonist and hCG, for final oocyte maturation (double trigger), in patients with low proportion of mature oocytes. Gynecol Endocrinol. 2015 Feb;31(2):145-7. doi: 10.3109/09513590.2014.978850. Epub 2014 Nov 11.</citation>
    <PMID>25385007</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2015</study_first_submitted>
  <study_first_submitted_qc>February 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2015</study_first_posted>
  <last_update_submitted>June 17, 2016</last_update_submitted>
  <last_update_submitted_qc>June 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Aya Mohr-Sasson</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>double triggering</keyword>
  <keyword>Oocyte maturation</keyword>
  <keyword>GNRH Agonist</keyword>
  <keyword>hCG</keyword>
  <keyword>IVF treatment</keyword>
  <keyword>immature oocytes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deslorelin</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

